TY - CHAP M1 - Book, Section TI - Neurocognitive Disorder and Cognitive Decline A1 - Au, Rhoda A1 - Piers, Ryan J. A1 - Ang, Ting Fang A2 - Boulton, Matthew L. A2 - Wallace, Robert B. PY - 2022 T2 - Maxcy-Rosenau-Last Public Health & Preventive Medicine, 16e AB - The global prevalence of dementia is over 24 million.1 This number is expected to reach over 81 million by the year 2040.1 The most common type of dementia is Alzheimer’s disease (AD) In the United States, it is estimated that more than 5.4 million people are living with AD, with approximately 5.2 million over the age of 65.2,3 Approximately 10.5% of 65-year-olds will develop AD dementia at some point in their life.4 There is evidence that after reaching the age of 65, the incidence of AD doubles every 5 years.5 The prevalence of AD is expected to increase rapidly as the “baby boomer generation” enters old age.2 The financial burden of caring for 5.2 million people with AD is $214 billion.6 This number will rise to $1.2 trillion by 2050 if the projected tripling to 16 million cases occurs.7 Importantly, these estimates are likely conservative, given the numerous causes of dementia. All of these factors underscore the critical importance of developing effective treatments. SN - PB - McGraw Hill CY - New York, NY Y2 - 2024/03/29 UR - accessmedicine.mhmedical.com/content.aspx?aid=1182668800 ER -